Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OncoSil Medical Ltd ( (AU:OSL) ) has provided an update.
OncoSil Medical Ltd reported record quarterly dose sales in Q3 FY25, reflecting a 233% increase compared to the previous year, driven by the growing clinical adoption of the OncoSil™ device. The company also received a $1.05 million R&D tax incentive and made strategic appointments and advancements, including the addition of Ms. Lel Smits to the Board of Directors and Ms. Shelley Steyn as CFO. Advisory Board meetings in the UK and Germany outlined strategic pathways for the device’s advancement, aiming to strengthen OncoSil’s position in the healthcare systems of these regions.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a medical device company specializing in localized treatments for patients with unresectable locally advanced pancreatic cancer. The company focuses on the OncoSil™ device, which is designed to deliver targeted radiotherapy for pancreatic cancer, with a market focus on expanding its clinical adoption and strategic positioning in key geographic areas such as the UK and Germany.
Technical Sentiment Signal: Buy
Current Market Cap: A$18.43M
For an in-depth examination of OSL stock, go to TipRanks’ Stock Analysis page.